Coverage: The Meridian legal market record (editorial).
The licensed territory is MENA as a region. No African country is named in the release or in the reporting reviewed, so the African link is the regional definition only and is recorded as such.
| Record ID | TX-AFR-2025-0011 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Exclusive licence, In-licensing |
| IP rights | patent, trade mark, regulatory data |
| Status | Signed |
| Qualifying date | 2025-04-09 |
| Sector | Life sciences · Pharmaceuticals – oncology |
| African markets | Multi-jurisdictional |
| Licensed territory | Middle East and North Africa (MENA); no country list in the release. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 3 source(s) |
| Last verified | 2026-10-25 |
Parties
- Hikma Pharmaceuticals PLC (United Kingdom): licensee
- pharmaand GmbH (pharma&) (Austria): licensor
Key terms
- Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: MENA region
Sources
- Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA, Hikma Pharmaceuticals, 2025-04-09
- Hikma and pharmaand partnership press release, April 2025, Hikma Pharmaceuticals (PDF release), 2025-04-09
- Hikma signs exclusive licensing agreement with pharma and to bring innovative oncology treatment to MENA, MarketScreener, 2025-04-10
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


